Helena Cornella
Overview
Explore the profile of Helena Cornella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1557
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Catela Ivkovic T, Cornella H, Voss G, Ku A, Persson M, Rigo R, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568709
Distant metastasis is the major cause of cancer-related deaths in men with prostate cancer (PCa). An in vivo functional screen was used to identify microRNAs (miRNAs) regulating metastatic dissemination of...
2.
Conboy C, Velez-Reyes G, Tschida B, Hu H, Kaufmann G, Koes N, et al.
Hepatol Commun
. 2019 Nov;
3(11):1496-1509.
PMID: 31701073
Each year, more than 25,000 people succumb to liver cancer in the United States, and this neoplasm represents the second cause of cancer-related death globally. R-spondins (RSPOs) are secreted regulators...
3.
Torrecilla S, Sia D, Harrington A, Zhang Z, Cabellos L, Cornella H, et al.
J Hepatol
. 2017 Aug;
67(6):1222-1231.
PMID: 28843658
Background & Aims: According to the clonal model of tumor evolution, trunk alterations arise at early stages and are ubiquitous. Through the characterization of early stages of hepatocarcinogenesis, we aimed...
4.
Catela Ivkovic T, Voss G, Cornella H, Ceder Y
Cancer Lett
. 2017 Apr;
407:113-122.
PMID: 28412239
During the last decades, basic and translational research has enabled great improvements in the clinical management of cancer. However, scarcity of complete remission and many drug-induced toxicities are still a...
5.
Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, et al.
Gut
. 2015 Dec;
66(3):530-540.
PMID: 26658144
Objective: Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately present disease progression. Molecular mechanisms underlying acquired resistance are still unknown. Herein, we characterise the role of tumour-initiating cells...
6.
Saha S, Parachoniak C, Ghanta K, Fitamant J, Ross K, Najem M, et al.
Nature
. 2015 Nov;
528(7580):152.
PMID: 26580013
No abstract available.
7.
Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, Mendez-Gonzalez J, et al.
Hepatology
. 2015 Feb;
61(6):1945-56.
PMID: 25645722
Unlabelled: Epigenetic deregulation has emerged as a driver in human malignancies. There is no clear understanding of the epigenetic alterations in hepatocellular carcinoma (HCC) and of the potential role of...
8.
Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, et al.
Nat Commun
. 2015 Jan;
6:6087.
PMID: 25608663
Intrahepatic cholangiocarcinoma (iCCA) is a fatal bile duct cancer with dismal prognosis and limited therapeutic options. By performing RNA- and exome-sequencing analyses, we report a novel fusion event, FGFR2-PPHLN1 (16%),...
9.
Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, et al.
Gastroenterology
. 2015 Jan;
148(4):806-18.e10.
PMID: 25557953
Background & Aims: Fibrolamellar hepatocellular carcinoma (FLC) is a rare primary hepatic cancer that develops in children and young adults without cirrhosis. Little is known about its pathogenesis, and it...
10.
Saha S, Parachoniak C, Ghanta K, Fitamant J, Ross K, Najem M, et al.
Nature
. 2014 Jul;
513(7516):110-4.
PMID: 25043045
Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are among the most common genetic alterations in intrahepatic cholangiocarcinoma (IHCC), a deadly liver cancer. Mutant IDH proteins in IHCC and other...